Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Head & Neck 2Dermatologic 2CNS 2Breast 2Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 250Carcinoma, Renal Cell 89Urinary Bladder Neoplasms 67Breast Neoplasms 41Carcinoma, Transitional Cell 37Colorectal Neoplasms 33Ovarian Neoplasms 32Melanoma 31Carcinoma, Non-Small-Cell Lung 31Kidney Neoplasms 30Neoplasms 28Neoplasm Metastasis 26Sarcoma 25Uterine Cervical Neoplasms 20Lung Neoplasms 20Endometrial Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 19Wilms Tumor 17Adenocarcinoma 17Stomach Neoplasms 16Pancreatic Neoplasms 16Carcinoma, Hepatocellular 16Triple Negative Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Metastatic Castration-resistant Prostate Cancer 13Esophageal Neoplasms 13Rhabdomyosarcoma 12Osteosarcoma 12Neuroblastoma 12Head and Neck Neoplasms 12

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Soft Tissue Neoplasms × Genitourinary × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡